Anzeige
Mehr »
Donnerstag, 18.06.2026 - Börsentäglich über 12.000 News
Warum dieser 19M-CAD-Silber-Junior fast 1 Mio. Unzen Gold versteckt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DMZL | ISIN: US56400P7069 | Ticker-Symbol: NNFN
Tradegate
18.06.26 | 08:01
3,493 Euro
+2,28 % +0,078
1-Jahres-Chart
MANNKIND CORPORATION Chart 1 Jahr
5-Tage-Chart
MANNKIND CORPORATION 5-Tage-Chart
RealtimeGeldBriefZeit
3,3803,48014:31
3,3803,48014:28

Aktuelle News zur MANNKIND Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
06.06.Data at ADA 2026 Highlights Key Findings from Clinical and Real-World Studies of MannKind's Afrezza (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems3
03.06.MannKind completes patient enrollment in nintedanib DPI trials3
03.06.MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF165Phase 1b INFLO-1 study data readout anticipated in Q3 2026 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company...
► Artikel lesen
MANNKIND Aktie jetzt für 0€ handeln
02.06.MANNKIND CORP - 8-K, Current Report1
31.05.FDA Approves MannKind's Afrezza For Children And Adolescents With Type 1 And Type 2 Diabetes5
29.05.MannKind wins FDA approval for inhaled insulin for children with type 1, type 2 diabetes3
29.05.MannKind gains FDA nod to expand inhaled insulin for children1
29.05.MannKind's Afrezza approved for children with diabetes1
29.05.MannKind Announces FDA Approval of Afrezza, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes502Enables dosing at the start of a meal, offering flexibility for children and adolescents as they manage school, sports, meals, and snacks throughout the dayApproval advances pediatric diabetes care...
► Artikel lesen
27.05.MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems13
22.05.MANNKIND CORP - 8-K, Current Report1
07.05.MannKind targets $110M-$120M 2026 FUROSCIX revenue as it nears May 29 and July 26 PDUFA catalysts7
07.05.MannKind drops after Q1 miss5
07.05.MannKind Q1 2026 slides: revenue up 15%, three catalysts ahead4
06.05.MannKind Reports First Quarter 2026 Financial Results and Provides Business Update443Q1 updates: Q1 2026 total revenues of $90.2M, +15% vs. Q1 2025Built out launch infrastructure and aligned field-based teams for upcoming launchesSettlement of senior convertible notes of $36.3M Program...
► Artikel lesen
06.05.MANNKIND CORP - 10-Q, Quarterly Report-
06.05.Partnerschaft mit United Therapeutics lässt MannKind-Aktie um 38 % steigen14
06.05.MannKind rises as collaboration with United Therapeutics expands6
06.05.MannKind develops inhaled ralinepag formulation for United Therapeutics12
06.05.MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases14
Weiter >>
66 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1